Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines

Although glycoconjugate vaccines are generally very efficacious, there is still a need to improve their efficacy, especially in eliciting a strong primary antibody response. We have recently described a new type of vaccine adjuvant based on a TLR7 agonist adsorbed to alum (Alum-TLR7), which is highl...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Sci Rep
Main Authors: Buonsanti, Cecilia, Balocchi, Cristiana, Harfouche, Carole, Corrente, Federica, Galli Stampino, Luisa, Mancini, Francesca, Tontini, Marta, Malyala, Padma, Bufali, Simone, Baudner, Barbara, De Gregorio, Ennio, Valiante, Nicholas M., O’Hagan, Derek T., Rappuoli, Rino, D’Oro, Ugo
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group 2016
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4954951/
https://ncbi.nlm.nih.gov/pubmed/27439378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep29063
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים